# Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma

> **NCT00446095** · PHASE1,PHASE2 · COMPLETED · sponsor: **Rigel Pharmaceuticals** · enrollment: 81 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** fostamatinib

## Key facts

- **NCT ID:** NCT00446095
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2010-04
- **Final completion:** 2010-10
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2016-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00446095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00446095, "Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00446095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*